

SEQUENCE LISTING

RECEIVED

NOV 13 2000

TECH CENTER 1800/2900

<110> Goulmy, Elsa

<120> METHOD FOR TYPING OF MINOR HISTOCOMPATIBILITY ANTIGEN
HA-1

<130> 2799/58994

<140> 09/269,250

<141> 1998-07-23

<160> 38

<170> PatentIn Ver. 2.1

<210> 1

<211> 377

<212> DNA

<213> Human

<400> 1

gtgagagcca cggggacacc gaggcctggg tggaagacag agccagaccc aagggaggat 60
ggagggaggg acttggggag gctcagaagg gagggaggct cagatggcag ggagggctgt 120
gtggaagagg ccatgacagc taaggctctg agggatgtgt aggagtttg tgggggagtc 180
cctgagcgta cactggctca agaggggtgc cactttattt tttttaaagg atctgatggc 240
aattaggagg gaaaggcaga ggaaatgtcc catgcacagg ctcagaaaca cggaaacaga 300
gaatgcattt gggggccaag gtgtggggtg ccgctgggtg aggatgaagg catgacaacg 360
ccaggcagaa gggcaat 377

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 2

gtgctgcctc ctggacactg

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 3

tggtcttcac cgtcatgcag

20

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 4

tggtcttcac cgtcacgcaa

20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 5

gcattctctg tttccgtgtt

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 6

cttaaggagt gtgtgctgca

20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 7

cttaaggagt gtgtgttgcg

20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 8

gctgtcatgg cctcttccac

20

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 9

gcattctctg tttccgtgtt

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 10

ggcagagagc cctcgcagcc

20

<210> 11

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 11

gtgtgtttgcg tgacggtg

18

<210> 12

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 12

gtgtgtttgcg tgacg

15

<210> 13

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 13

tgtgtgttgc gtagcg

16

<210> 14

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 14

tgtgtgctgc atgacggtg

19

<210> 15

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 15

tgtgtgctgc atgacggt

18

<210> 16

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 16

gtgtgctgca tgacggtg

18

<210> 17

<211> 9

<212> PRT

<213> Human

<220>

<221> SITE

<222> (3)

<223> Wherein Xaa at position 3 represents a histidine
(H) or an arginine (R) residue.

<400> 17

Val Leu Xaa Asp Asp Leu Leu Glu Ala

1

5

<210> 18

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 18

gctcctgcat gacgctctgt ctgca

25

<210> 19

<211> 24
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer

 <400> 19
 gacgtcgtcg aggacatctc ccat 24

 <210> 20
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer

 <400> 20
 gaagggcaca gcaatcgtct ccagg 25

 <210> 21
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer

 <400> 21
 ccttgagaaa cttaaggagt gtgtgctgca 30

 <210> 22
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer

 <400> 22
 ccttgagaaa cttaaggagt gtgtgttgcg 30

 <210> 23

<211> 33
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 23
ccggcatgga cgtcgtcgag gacatctccc atc

33

<210> 24
<211> 30
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 24
ctacttcagg ccacagcaat cgtctccagg

30

<210> 25
<211> 27
<212> DNA
<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(27)

<220>

<223> Description of Artificial Sequence: Exon
Fragments

<400> 25
gtg ttg cgt gac gac ctc ctt gag gcc
Val Leu Arg Asp Asp Leu Leu Glu Ala
1 5

27

<210> 26
<211> 9
<212> PRT
<213> Artificial Sequence

<223> Description of Artificial Sequence: Exon
Fragments

<400> 26

Val Leu Arg Asp Asp Leu Leu Glu Ala

1

5

<210> 27

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(27)

<220>

<223> Description of Artificial Sequence: Exon
Fragments

<400> 27

gtg ctg cat gac gac ctc ctt gag gcc

27

Val Leu His Asp Asp Leu Leu Glu Ala

1

5

<210> 28

<211> 9

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Exon
Fragments

<400> 28

Val Leu His Asp Asp Leu Leu Glu Ala

1

5

<210> 29

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Exon
Fragments

<400> 29
gtgttgcggtg acggtgagag cca 23

<210> 30
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Exon
Fragments

<400> 30
ctcactccga ctctcccag cagacctct tgaggcc 37

<210> 31
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (1)..(39)

<220>
<223> Description of Artificial Sequence: PCR Product

<400> 31
gag tgt gtg ttg cgt gac gac ctc ctt gag gcc cgc cgc 39
Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg
1 5 10

<210> 32
<211> 13
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: PCR Product

<400> 32
Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg
1 5 10

<210> 33

<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (1)..(39)

<220>
<223> Description of Artificial Sequence: PCR Product

<400> 33
gag tgt gtg ctg cat gac gac ctc ctt gag gcc cgc cgc 39
Glu Cys Val Leu His Asp Asp Leu Leu Glu Ala Arg Arg
1 5 10

<210> 34
<211> 13
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: PCR Product

<400> 34
Glu Cys Val Leu His Asp Asp Leu Leu Glu Ala Arg Arg
1 5 10

<210> 35
<211> 78
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (1)..(78)

<220>
<223> Description of Artificial Sequence: PCR Product

<400> 35
gag tgt gtg ttg cgt gac gac ctc ctt gag gcc cgc cgc gag tgt gtg 48
Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg Glu Cys Val
1 5 10 15

ctg cat gac gac ctc ctt gag gcc cgc cgc 78
Leu His Asp Asp Leu Leu Glu Ala Arg Arg

<210> 36

<211> 26

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: PCR Product

<400> 36

Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg Glu Cys Val
 1 5 10 15

Leu His Asp Asp Leu Leu Glu Ala Arg Arg
 20 25

<210> 37

<211> 9

<212> PRT

<213> Human

<220>

<221> SITE

<222> (2)

<223> Wherein Xaa at position 2 represents Isoleucine or
 Leucine

<400> 37

Tyr Xaa Thr Asp Arg Val Met Thr Val
 1 5

<210> 38

<211> 8

<212> PRT

<213> Human

<400> 38

Val Leu His Asp Leu Leu Glu Ala
 1 5